Physician profile
Dennis Lyons
NPI 1265476766
$1,343.74
in general payments reported to CMS, 2019-2025
15 companies · $471 in 2025
The $471 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $47.25 · 2021: $11.83 · 2022: $75.00 · 2023: $91.32 · 2024: $512 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,073.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $341.92 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Biotissue Holdings INC. | $190.56 | 2024 | |
| Coopervision INC. | $119.33 | 2019-2024 | Misight Contact Lens |
| Alexion Pharmaceuticals, INC. | $91.32 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $88.64 | 2024 | |
| Lkc Technologies, INC. | $85.86 | 2025 | |
| Alcon Vision LLC | $75.97 | 2024 | Total30 |
| Horizon Therapeutics Plc | $75.00 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $65.71 | 2025 | |
| Dompe US, INC. | $55.00 | 2025 | Oxervate |
| Allergan, INC. | $47.25 | 2020 | |
| Optovue, INC. | $43.34 | 2019 | |
| Visioneering Technologies, INC. | $34.21 | 2019 | |
| Sun Pharmaceutical Industries INC. | $17.80 | 2025 | |
| Kala Pharmaceuticals, INC. | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.